---
title: "Predictors and Trends of One-Day Discharge After Radical Prostatectomy in SEER-Medicare Patients"
id: "medrxiv-23-geographic-and-clinical-predictors-of-one-day-discharge-after-radical"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-23-geographic-and-clinical-predictors-of-one-day-discharge-after-radical"
content_type: "clinical_feed_article"
specialty: "Urology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.16.26363208v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Predictors and Trends of One-Day Discharge After Radical Prostatectomy in SEER-Medicare Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-23-geographic-and-clinical-predictors-of-one-day-discharge-after-radical
- **Specialty:** [Urology](https://medichelpline.com/clinical-feed/urology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.16.26363208v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective SEER-Medicare cohort study assessed geographic patterns, temporal trends, and predictors of **one-day discharge** after radical prostatectomy in Medicare beneficiaries diagnosed 2008–2019. - The analytic cohort included 40,728 patients treated at 1,048 hospitals after exclusions for metastatic disease, HMO coverage, and age <66. - Overall, 52.4% of patients were discharged on postoperative day 1; the rate rose from 48.8% in 2008–2013 to 56.8% in 2014–2019. - **Robotic surgery** was strongly associated with higher odds of one-day discharge (adjusted OR 2.88, 95% CI 2.54–3.27). - Treatment at a National Cancer Institute-designated comprehensive cancer center was associated with increased odds (aOR 1.88, 95% CI 1.28–2.76). - Disparities identified: Black versus White patients (aOR 0.76, 95% CI 0.70–0.82), unmarried versus married (aOR 0.79, 95% CI 0.73–0.85), and lowest versus highest neighborhood socioeconomic quintile (aOR 0.86, 95% CI 0.79–0.94) had lower odds of one-day discharge. - Odds of one-day discharge were 31% higher in the late (2014–2019) versus early (2008–2013) period (aOR 1.31, 95% CI 1.20–1.43). - Regional differences were reported but were attenuated in sensitivity analyses. - Authors conclude one-day discharge has become the predominant practice among Medicare beneficiaries, largely driven by robotic approach and treatment era, and note persistent racial and socioeconomic differences that merit further study.
## Clinical Analysis & Structured Key Points
Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study | medRxiv Skip to main content Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study View ORCID Profile Jacob Hanna , View ORCID Profile Megan R. Shanahan , Jennifer Sykes , Farzin Khosrow-Khavar , Thomas L. Jang , View ORCID Profile Hari S. Iyer doi: https://doi.org/10.64898/2026.09.16.26363208 Jacob Hanna 1 Rutgers Robert Wood Johnson Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jacob Hanna Megan R. Shanahan 2 Rutgers Cancer Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Megan R. Shanahan Jennifer Sykes 1 Rutgers Robert Wood Johnson Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Farzin Khosrow-Khavar 3 Rutgers School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Thomas L. Jang 2 Rutgers Cancer Institute; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hari S. Iyer 4 Dana Farber Cancer Institute Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Hari S. Iyer For correspondence: hai161{at}mail.harvard.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Objectives: To study the geographic patterns, temporal trends, and predictors of one-day discharge following radical prostatectomy. Methods: We conducted a retrospective cohort study of men diagnosed with prostate cancer from 2008 to 2019 in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Patients with metastatic disease, health maintenance organization coverage, or age younger than 66 years were excluded. Type of surgery and length of stay were derived from inpatient claims. We compared one-day discharge by early (2008–2013) and late (2014–2019) periods, by census region, and by individual- and facility-level factors, and used generalized estimating equations to estimate adjusted odds ratios (aOR) with 95% confidence intervals (CI), accounting for clustering of patients within hospitals. Results: Among 40,728 patients treated at 1,048 hospitals, 52.4% were discharged on postoperative day 1, increasing from 48.8% (2008–2013) to 56.8% (2014–2019). Higher odds of one-day discharge were associated with robotic surgery (aOR 2.88, 95% CI 2.54–3.27) and treatment at a National Cancer Institute-designated comprehensive cancer center (aOR 1.88, 95% CI 1.28–2.76). Black versus White patients (aOR 0.76, 95% CI 0.70–0.82), unmarried versus married patients (aOR 0.79, 95% CI 0.73–0.85), and patients in the lowest versus highest neighborhood socioeconomic quintile (aOR 0.86, 95% CI 0.79–0.94) had lower odds. Odds were 31% higher in the late versus early period (aOR 1.31, 95% CI 1.20–1.43). Regional differences were attenuated in sensitivity analyses. Conclusions: One-day discharge after radical prostatectomy has increased over time and is now the predominant practice among Medicare beneficiaries, driven primarily by robotic surgery and treatment era. Persistent racial and socioeconomic differences in discharge patterns warrant further research into whether early discharge is equally safe and beneficial across patient populations. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Rutgers University Institutional Review Board, Study ID Pro2021001673. Informed consent was waived because the study analyzed de-identified secondary data (SEER-Medicare linked database) under a National Cancer Institute data use agreement. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data underlying this study are third-party data from the SEER-Medicare linked database, obtained from the U.S. National Cancer Institute (NCI) under a data use agreement. The authors are not permitted to share these data publicly because they contain protected health information governed by NCI and the Centers for Medicare & Medicaid Services. Other researchers may request access to identical SEER-Medicare data through the NCI Healthcare Delivery Research Program (https://healthcaredelivery.cancer.gov/seermedicare/obtain/), subject to approval of a data request and execution of a data use agreement. The authors did not have any special access privileges that others would not have. SAS code used for cohort construction and analysis is available from the corresponding author on request. https://healthcaredelivery.cancer.gov/seermedicare/obtain/ Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 17, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study Jacob Hanna , Megan R. Shanahan , Jennifer Sykes , Farzin Khosrow-Khavar , Thomas L. Jang , Hari S. Iyer medRxiv 2026.09.16.26363208; doi: https://doi.org/10.64898/2026.09.16.26363208 Share This Article: Copy Citation Tools Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study Jacob Hanna , Megan R. Shanahan , Jennifer Sykes , Farzin Khosrow-Khavar , Thomas L. Jang , Hari S. Iyer medRxiv 2026.09.16.26363208; doi: https://doi.org/10.64898/2026.09.16.26363208 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (618) Allergy and Immunology (903) Anesthesia (334) Cardiovascular Medicine (4822) Dentistry and Oral Medicine (479) Dermatology (416) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1631) Epidemiology (15962) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7055) Geriatric Medicine (733) Health Economics (1066) Health Informatics (5053) Health Policy (1435) Health Systems and Quality Improvement (1772) Hematology (586) HIV/AIDS (1346) Infectious Diseases (except HIV/AIDS) (16298) Intensive Care and Critical Care Medicine (1174) Medical Education (670) Medical Ethics (155) Nephrology (725) Neurology (7285) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1243) Occupational and Environmental Health (1005) Oncology (3611) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (472) Palliative Medicine (139) Pathology (709) Pediatrics (1804) Pharmacology and Therapeutics (737) Primary Care Research (768) Psychiatry and Clinical Psychology (5910) Public and Global Health (9765) Radiology and Imaging (2429) Rehabilitation Medicine and Physical Therapy (1454) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Evaluating Focal Therapy for Localized Prostate Cancer: A Shift in Perspectives?](https://medichelpline.com/clinical-feed/stat-news-0-focal-therapy-for-localized-prostate-cancer-has-divided-physicians-will-new.md)
- [Cancer type–specific chromatin regulator mutations linked to better survival after immune checkpoi](https://medichelpline.com/clinical-feed/medrxiv-17-cancer-type-specific-profiling-of-chromatin-regulator-mutations-identifies.md)
- [Hormonal Management in Older Transgender and Gender Diverse Adults: Case-Based Considerations](https://medichelpline.com/clinical-feed/pubmed-42274359.md) (DOI: 10.1210/clinem/dgag231)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)
- [Adjusting unmet need for contraception by including husband’s virility in the Revised algorithm](https://medichelpline.com/clinical-feed/plos-one-2-incorporating-husband-s-influence-in-estimating-unmet-need-for-contraception.md)

## Navigation
- [← Back to Urology Feed](https://medichelpline.com/clinical-feed/urology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.